GOLD stage I is not a COPD risk factor

A retrospective analysis of data from the Cardiovascular Health Study (CHS) performed by Mannino et al. concludes that older adults with borderline abnormal spirometry results have an increased risk of death and hospitalisations related to chronic obstructive pulmonary disease (COPD). The all-cause mortality rate from the analysis by Mannino et al. merely confirms many previous reports. However, the mechanism is not obstructive lung disease since the vital capacity (FVC), aptly named by British surgeon John Hutchinson more than 150 years ago, is a stronger predictor than forced expiratory volume in 1 s (FEV₁), and respiratory muscle weakness accounts for much of the relationship.

It is intuitive that patients with COPD must make a transition from normal spirometry to clinically relevant airway obstruction. However, only a small minority of adults with borderline abnormal spirometric results will ever develop COPD, regardless of their smoking status. For example, in the Lung Health Study, only 10% of the variability in the subsequent decline in lung function in continuing smokers was predicted by baseline spirometric results, even when bronchodilator responsiveness and airway reactivity were included in the predictive model. Therefore, very few participants in the CHS whose FEV₁/FVC was below the middle quintile (falling into the arbitrary GOLD stage I) have ever developed COPD. In fact, chronic bronchitis, emphysema, asthma and dyspnoea (as reported at study entry) were not independent predictors of a subsequently more rapid decline in lung function in the CHS cohort.

The paper by Mannino et al. suggests that GOLD stage I predicted “COPD-related” hospitalisations. However, the medical records were not examined for spirometric test results. I believe that the vast majority of these hospitalisations were not due to an exacerbation of COPD. In one recent study only one-third of 800 consecutive patients with a discharge diagnosis of COPD had a spirometric test. A history of chronic cough, dyspnoea on exertion and cigarette smoking in hospitalised patients is more likely to be associated with heart failure or pneumonia than COPD.

In CHS participants with a normal baseline FEV₁ (GOLD stage I), 11 years of follow-up was not sufficiently long for even the continuing smokers to have lost enough lung function to have developed a COPD exacerbation. Current smokers in the CHS had an average of only 48 ml/year during the first 7 years of follow-up, which extrapolates to a loss of only 0.5 litres after 11 years. The average baseline FEV₁ was 2.4 litres in men and 1.8 litres in women.

In summary, as the CHS investigator responsible for spirometric testing in this study, I am not convinced by the analyses of Mannino and colleagues that GOLD stage I spirometry was a risk factor for COPD morbidity or mortality.

Paul L. Enright
The University of Arizona, 4460 East Ina Road, Tucson, Arizona 85718, USA; lunggy@u.arizona.edu

The author is the Principal Investigator for the Pulmonary Reading Center of the Cardiovascular Health Study. The author (and has been) a consultant to several pharmaceutical companies for quality assurance programs for pulmonary function testing in clinical trials.

References

What defines abnormal lung function?

A major concern with the GOLD criteria for defining chronic obstructive pulmonary disease (COPD) is that the use of 70% as a fixed cut-off for forced expiratory volume in 1 s (FEV₁) will add a significant number of false positives compared with the use of a true lower limit of normal. The recent paper in Thorax by Mannino et al. argues that this false positive rate is acceptable. The authors concluded that these false positive subjects had an increased hazard of death when compared with those with FEV₁ >70%. This finding is to be expected because a group with a less good level of lung function is being compared with a group with better lung function, even though both groups are within the normal range. For example, in the Copenhagen City Heart Study data, if the 8101 subjects whose FEV₁% in standardised residuals (SR) was >0 (i.e., above predicted) are compared with the 1876 subjects whose FEV₁%SR was between 0 and −0.5, the latter have a hazard ratio (HR) for death of 1.09 [95% CI 1.02 to 1.17] (Dr Peter Lange, personal communication). If, instead, those above predicted are compared with the 1292 subjects with FEV₁%SR between −0.5 and −1.0, then the latter have a HR of 1.24 [95% CI 1.14 to 1.34]. So these 3168 normal subjects have results for FEV₁% well within the normal range but have an increased HR for death when compared with that part of the population with the best lung function. This effect is even more true for FEV₁%SR <0.5.

Is it then justifiable to label an asymptomatic individual with a disease on the basis of spirometric parameters that are within the accepted normal range just because they have an increased risk of death? If this argument is further developed, then male sex is also a disease since life expectancy in men is lower than in women.

Labelling an individual as having a disease can have a bad psychological effect and, if there is as yet no proven treatment for the presumed condition, this is an even more unacceptable state of affairs. Disease has been defined as “an impairment of health or a condition of abnormal functioning” (www. hyperdictionary.com) and as “a disorder of structure or function in a human, especially one that produces specific symptoms or that affects a specific part” (Oxford English Dictionary). The current GOLD definition of COPD does not meet these requirements for defining this disease and must be changed. Researchers may need to find another term to describe their point of interest rather than labelling normal individuals incorrectly as having the disease COPD.

Martin R Miller
Department of Medicine, University Hospital Birmingham NHS Trust, Birmingham B29 6JD, UK; martin.miller@uhb.nhs.uk

Competing interests: None.

References

Definition of COPD GOLD stage I

Chronic obstructive pulmonary disease (COPD) is an important disease from a public health perspective, with a number of preventable occupational, environmental and personal risk factors. The Global Initiative for Obstructive Lung Disease (GOLD) was implemented to raise awareness of COPD and to improve the prevention and treatment of this lung disease. A concern has been raised regarding use of the criterion “forced expiratory volume in 1 s/forced vital capacity (FEV₁/FVC) <0.70” in the definition of GOLD stage I which may lead to overdiagnosis of COPD, particularly in older individuals.

To address this controversy, Mannino and colleagues assessed COPD-related hospitalisations and mortality among 5201 individuals aged 65 years and older who had participated in the Cardiovascular Health Study. The authors concluded that study participants they termed “potentially overdiagnosed” (those with FEV₁/FVC <0.70 who also had an FEV₁/FVC ratio above or equal to the lower limit of normal (LLN)) were more likely to die and to have COPD-related hospitalisations during the 11 year follow-up period than “normals” (those with FEV₁/FVC >0.70 and FVC >80% predicted who were asymptomatic). Based on...
this finding, the authors suggested that using the LLN criterion may miss some older individuals who could benefit from intervention.

This conclusion was based on the analysis where all “potentially overdiagnosed” participants classified as GOLD stages I–IV were grouped together and compared with the “normal” group, with a resulting mortality hazard ratio (HR) of 1.3 (95% CI 1.1 to 1.5). However, as noted above, the controversy focuses on individuals classified in GOLD stage I. Persons with FEV\textsubscript{1}/FVC <0.70 and FEV\textsubscript{1}/FVC ≥LLN within GOLD stage I represent the majority (72%) of the “potentially overdiagnosed” individuals. It is possible that some of these individuals would have benefited from further clinical evaluation and treatment through adherence to the GOLD criteria. The adjusted mortality HR for this subgroup was 1.1 (95% CI 0.96 to 1.3) compared with the “normal” group. The magnitude of the HR is quite small and the confidence interval includes 1.0. This contrasts with the significantly raised adjusted mortality HR of 1.4 (95% CI 1.1 to 1.7) for the GOLD stage I subgroup with FEV\textsubscript{1}/FVC < LLN. The study results therefore do not substantiate a significant increase in all-cause mortality among the GOLD stage I subgroup that is “potentially overdiagnosed.”

The authors noted that while the statistically significant increase in the risk of hospitalisation with mention of COPD in the GOLD stage I subgroup of “potentially overdiagnosed” individuals compared with the “normal” group. However, individuals with respiratory symptoms but normal lung function (i.e., GOLD stage 0 in the paper) had a similar increase in hospitalisations, both before and after adjustments. Because the “potentially diagnosed” subgroup included individuals with symptoms consistent with COPD, the observed increases in hospitalisations in mention of COPD could be attributable to the presence of respiratory symptoms rather than to any lung function abnormalities. The authors could address this confounding of lung function differences by symptoms by re-analysing the hospitalisations after excluding individuals with symptoms in the “potentially diagnosed” subgroups.

An additional concern with the study relates to the potential for diagnostic bias. The authors indicate that they analysed hospitalisations “with mention of COPD” but do not indicate whether or not these hospitalisations were attributable to COPD. Because the entire study population underwent initial spirometric testing, it is possible that some of the treating physicians were aware of the spirometry report and may therefore have been more likely to have mentioned COPD on discharge for those patients with an FEV\textsubscript{1}/FVC ratio <0.70, even if COPD was not contributory to the hospitalisation. The authors could address this potential for diagnostic bias by re-analysing the results, restricting the outcome of interest to hospitalisations for which COPD or other respiratory illness was the primary discharge diagnosis.

Adherence to the FEV\textsubscript{1}/FVC <0.70 criterion in GOLD stage I will potentially identify an additional 5.4 million individuals (58%) in the US population as having COPD compared with use of the LLN criterion. This large group of individuals will experience anxiety as well as financial and social costs. However, they may not benefit from sufficient documentation of a potential benefit. We agree with others who recommend reconsideration of the FEV\textsubscript{1}/FVC ratio <0.70 as a criterion for identifying mild COPD.

Edward L Petsonk, Eva Hnizdo, Michael Attilfield
Division of Respiratory Disease Studies, National Institute for Occupational Safety and Health, Morgantown, West Virginia, USA

Correspondence to: Dr Edward L Petsonk, National Institute for Occupational Safety and Health, Morgantown, West Virginia 26505, USA; elp2@cdc.gov

This contribution was prepared entirely by US Federal Government employees as part of their official duties, it is therefore in the public domain in the USA. The findings and conclusions in this paper have not been formally disseminated by the National Institute for Occupational Safety and Health (NIOSH) and should not be construed to represent any official policy or position.

Competing interests: None.

References
4 Kershjans HAM. The GOLD classification has not advanced understanding of COPD. Am J Respir Crit Care Med 2004;170:212–3.
5 Medbå A, Melbye H. Lung function testing in the elderly: can we still use FEV\textsubscript{1}/FVC <0.70 as a criterion for COPD? Am J Respir Crit Care Med 2007;101:1097–105.

Authors’ reply
We thank Drs Enright, Miller and Petsonk et al for their insightful comments regarding our recently published paper, which can be summarised as follows: (1) use of the fixed forced expiratory volume in 1 s/forced vital capacity (FEV\textsubscript{1}/FVC) ratio of 0.70 rather than a lower limit of normal greatly “overdiagnoses” chronic obstructive pulmonary disease (COPD) and is thus detrimental to both public health and the psychological health of patients; (2) GOLD stage I COPD does not represent disease but is, in most people, simply normal ageing; (3) our measure of [244x270]overdiagnoses [244x270]potential overdiagnosis. The debate that is going on at present about the different criteria for airflow obstruction is a healthy one that can best be informed by analyses such as ours and the subsequent discussion that such analyses generate. This is how science evolves. We are happy to have stimulated a lively discussion and anticipate that it will lead to further studies and analyses.

The question of whether the GOLD stage I classification really just represents “normal” ageing in most people is another area of ongoing debate. Although we do not dispute that the FEV\textsubscript{1}/FVC decreases with ageing and that not everyone meeting GOLD stage I criteria has “disease,” we also know that, on average, older individuals with better lung function tend to live longer and are more healthy than those with worse lung function.2 We also know that those with respiratory symptoms fare worse than do those without such symptoms. Finally, while we acknowledge the potentially negative psychological consequences of labelling someone as having a chronic disease, patients understand the concept of disease staging, and telling someone that they have potentially early stage COPD may in fact have some positive public health consequences. For instance, one study has noted that patients who underwent spirometric tests and were found to have “mild” disease were more likely than subjects with “normal” lung function to stop smoking, and that cessation rates were even higher in those who were told they have “moderate” and “severe” disease. Again, we anticipate that trying to address the questions surrounding normal ageing versus the development of early disease will lead to further studies and analyses of longitudinal data.

As to whether our measure of COPD-related hospitalisations was too inclusive, we agree with Drs Enright, Miller and Petsonk et al that the link between COPD and other diseases (such as pneumonia, congestive heart failure and lung cancer) has been well established, and many hospitalisations in patients with COPD are for these co-morbid conditions.4 However, lung function impairment does consistently seem to increase the risk of such hospitalisations.

In conclusion, the letters published here raise some important issues at the intersection of how we define disease (particularly in epidemiological studies) and how we use clinical criteria to classify the severity of disease in our patients with respiratory disease, we use clinical criteria such as the presence of symptoms or quality of life impairment to guide treatment. This is particularly true in mild disease where the best interventions are smoking cessation, weight loss and exercise.

David M Mannino
Division of Pulmonary, Critical Care Medicine, University of Kentucky Medical Center, Lexington, Kentucky, USA

A Sonia Buist
Department of Medicine, Oregon Health and Science University, Portland, Oregon, USA

Downloaded from http://thorax.bmj.com/ on June 23, 2017 - Published by group.bmj.com
Definition of COPD GOLD stage I

Edward L Petsonk, Eva Hnizdo and Michael Attfield

Thorax 2007 62: 1107-1108

Updated information and services can be found at:
http://thorax.bmj.com/content/62/12/1107.3

These include:

References
This article cites 4 articles, 1 of which you can access for free at:
http://thorax.bmj.com/content/62/12/1107.3#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/